{"nctId":"NCT02227862","briefTitle":"Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)","startDateStruct":{"date":"2014-06","type":"ACTUAL"},"conditions":["Type 1 Diabetes"],"count":558,"armGroups":[{"label":"Mylan's Insulin Glargine","type":"EXPERIMENTAL","interventionNames":["Drug: Mylan's insulin glargine"]},{"label":"Lantus®","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lantus®"]}],"interventions":[{"name":"Mylan's insulin glargine","otherNames":[]},{"name":"Lantus®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with an established diagnosis of T1DM per ADA 2014 criteria\n* Body mass index (BMI) of 18.5 to 35 kg/m2 at screening (both values inclusive).\n* Glycosylated hemoglobin (HbA1c) ≤9.5% at screening.\n* Hemoglobin ≥9.0 g/dL at screening.\n\nExclusion Criteria:\n\n* History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions.\n* History of use of animal insulin within the last 3 years or use of biosimilar insulin glargine at any time prior.\n* History of use of a regular immunomodulator therapy in the 1 year prior to screening.\n* History of ≥2 episodes of severe hypoglycemia within the 6 months before screening or history of hypoglycemia unawareness (a sample questionnaire is provided in Appendix I), as judged by the investigator.\n* History of ≥1 episodes of diabetic ketoacidosis or emergency room visits for uncontrolled diabetes leading to hospitalization within the 6 months prior to screening.\n* Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg) or hepatitis C (HCVAb) antibodies at screening.\n* History of drug or alcohol dependence or abuse during the 1 year prior to screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to 24 Weeks","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"0.054"},{"groupId":"OG001","value":"0.11","spread":"0.054"}]}]}]},{"type":"SECONDARY","title":"Summary of Actual and Change From Baseline in HbA1c","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.599"},{"groupId":"OG001","value":"0.09","spread":"0.526"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.633"},{"groupId":"OG001","value":"0.25","spread":"0.595"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.81","spread":"4.485"},{"groupId":"OG001","value":"0.09","spread":"4.507"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"4.281"},{"groupId":"OG001","value":"0.43","spread":"4.455"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 8-point SMBG Profile Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.038","spread":"2.3751"},{"groupId":"OG001","value":"-0.095","spread":"1.5012"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.082","spread":"1.5032"},{"groupId":"OG001","value":"-0.082","spread":"1.5267"}]}]}]},{"type":"SECONDARY","title":"Change in Total Daily Insulin Dose Per Unit Body Weight From Baseline Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0203","spread":"0.09962"},{"groupId":"OG001","value":"0.0127","spread":"0.10871"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0278","spread":"0.1044"},{"groupId":"OG001","value":"0.0138","spread":"0.11372"}]}]}]},{"type":"SECONDARY","title":"Rate of Hypoglycemic Events Per 30 Days Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.162","spread":"9.0724"},{"groupId":"OG001","value":"-4.93","spread":"8.3815"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.241","spread":"9.214"},{"groupId":"OG001","value":"-5.765","spread":"8.3658"}]}]}]},{"type":"SECONDARY","title":"Hypoglycemia Occurrence","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"273","spread":null},{"groupId":"OG001","value":"269","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"249","spread":null},{"groupId":"OG001","value":"249","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"246","spread":null},{"groupId":"OG001","value":"243","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Local and Systematic Reactions","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Total Insulin Antibody Percent Binding for Mylan's Insulin Glargine Assay Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3063","spread":"7.22075"},{"groupId":"OG001","value":"0.3592","spread":"7.16624"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9591","spread":"8.51754"},{"groupId":"OG001","value":"-1.0634","spread":"8.42794"}]}]}]},{"type":"SECONDARY","title":"Change in Total Insulin Antibody Percent Binding for Lantus Assay Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.215","spread":"7.3298"},{"groupId":"OG001","value":"0.157","spread":"7.411"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.896","spread":"8.5610"},{"groupId":"OG001","value":"-1.233","spread":"8.623"}]}]}]},{"type":"SECONDARY","title":"Change in Cross-reactive Insulin Antibody Percent Binding for Mylan's Insulin Glargine Assay Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.363","spread":"7.1081"},{"groupId":"OG001","value":"0.27","spread":"7.1204"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.132","spread":"8.3911"},{"groupId":"OG001","value":"-1.21","spread":"8.4096"}]}]}]},{"type":"SECONDARY","title":"Change in Cross-reactive Insulin Antibody Percent Binding for Lantus Assay Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.265","spread":"7.2543"},{"groupId":"OG001","value":"0.055","spread":"7.3985"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.060","spread":"8.4414"},{"groupId":"OG001","value":"-1.367","spread":"8.6848"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With HbA1c < 7%","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":280},"commonTop":["Hypoglycaemia","Nasopharyngitis","Upper respiratory tract infection","Influenza","Headache"]}}}